LONDON, July 10 — John Hardy, the British geneticist and neuroscientist who first proposed that amyloid-beta accumulation is the primary cause of Alzheimer’s disease, has seen his hypothesis become the central framework for three decades of drug development. Hardy continues his work at University College London, where he holds a professorship. The amyloid cascade hypothesis was published in the journal Science in 1992, co-authored with Gerald Higgins.
At the time, the idea that a single molecular process could explain the complex neurodegeneration of Alzheimer’s was a bold claim. According to the scientific record, Hardy and Higgins argued that the accumulation of amyloid-beta in the brain sets off a chain reaction that ultimately destroys neurons.
Hardy’s own laboratory work in the 1990s provided key genetic evidence. He identified mutations in the amyloid precursor protein gene on chromosome 21 that cause early-onset familial Alzheimer’s. These mutations, found in families where the disease strikes early, were a direct link between the gene and the protein.
Officials in the field have confirmed that this discovery gave the hypothesis its strongest early support. The record shows that Hardy also contributed to the discovery of mutations in two other genes — presenilin 1 and presenilin 2.
Both are involved in the cellular machinery that produces amyloid-beta. Together with the APP mutations, these genetic findings created a clear picture: faulty genes lead to excess amyloid, and excess amyloid leads to Alzheimer’s. For researchers, this was a causal chain, not just a correlation.
Over the course of his career, Hardy has published more than 800 scientific papers. His work has earned two of the largest prizes in biomedicine. He received the Breakthrough Prize in Life Sciences in 2016 and the Brain Prize in 2018.
These awards reflect the impact of his hypothesis on the field. The strategic context is significant.
For roughly thirty years, the vast majority of Alzheimer’s drug development has been built on the amyloid cascade hypothesis. Pharmaceutical companies invested billions of dollars into compounds designed to clear amyloid-beta from the brain. Some of these drugs have shown modest success in slowing cognitive decline in early-stage patients.
Others have failed in late-stage clinical trials.
The evidence base expands
Hardy has not limited his research to amyloid. According to the source material, he has also studied the role of tau protein and neuroinflammation in Alzheimer’s. Tau is another protein that forms tangles inside neurons, and its accumulation correlates more closely with cognitive decline than amyloid plaques do.
Neuroinflammation — the brain’s immune response — is now understood to play a role in the disease’s progression. This broader focus reflects the evolution of the field.
The amyloid cascade hypothesis has been refined over time. Critics have pointed out that many older people have amyloid plaques in their brains without developing dementia, and that drugs that clear amyloid do not always stop cognitive decline. Hardy’s own work on tau and inflammation suggests he recognizes the complexity.
Still, the core of the hypothesis remains influential. The genetic evidence that Hardy helped uncover is not in dispute.
Mutations in APP, PSEN1, and PSEN2 cause early-onset Alzheimer’s, and those mutations all increase production of a specific form of amyloid-beta. For families with these rare genetic forms, the cause is clear.
What to watch next
The next phase of research will likely focus on combination therapies — drugs that target amyloid, tau, and inflammation simultaneously. Clinical trials are already testing this approach. Hardy’s contributions to understanding each of these mechanisms give him a unique perspective on how they interact.
The scientific community continues to debate the precise timing of amyloid’s role. Some researchers argue that amyloid accumulation begins years or even decades before symptoms appear, and that treatment must start early.
Others contend that tau pathology is the more important target once symptoms are present. Hardy’s published work addresses both sides of this argument. For now, the amyloid cascade hypothesis remains the dominant model in Alzheimer’s research.
It has driven the development of the only disease-modifying treatments that have reached the market. Whether those drugs prove to be the first step toward effective therapies or a detour on the path to a cure will depend on data from ongoing trials. Consult your doctor for medical advice.
